NPM1 and acute myeloid leukemia: These conclusions were confirmed in another recent study showing in the group of AML patients with normal karyotype and mutated NPM1 that there is a marked difference in the relapse risk, as well in the survival, between patients with low and high FLT3-ITD/WT ratio [77].